What is Acumen Pharmaceuticals, Inc.'s earnings per share (EPS)?

Acumen Pharmaceuticals, Inc. (ABOS) reported diluted earnings per share of -$2.00 for fiscal year 2025. This represents a -17.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Acumen Pharmaceuticals, Inc. (ABOS) Financials

ABOS

FY2025 annual

Net Income -$121.3M -18.6% YoY

EPS (Diluted) -$2.00 -17.0% YoY

Free Cash Flow -$115.6M -34.1% YoY

Operating Cash Flow -$115.5M -34.0% YoY

Market Cap $201.8M as of Sep 14, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 3.5x on $57.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ABOS SEC filings page.

This page shows Acumen Pharmaceuticals, Inc. (ABOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ABOS FY2025 2026-08-30

Acumen's R&D-led development program consumes cash while shrinking equity reduces the company's financial cushion

By FY2025, operating cash flow of -$115.5M nearly matched free cash flow of -$115.6M, while capital expenditures were only $88K. Cash consumption is therefore driven primarily by the research program, not by heavy physical reinvestment.

R&D spending expanded from $12.3M in FY2021 to $104.9M in FY2025, making scientific investment the principal visible driver of the widening operating loss.

Equity fell from $267.0M in FY2023 to $70.4M in FY2025, so accumulated losses materially reduced the balance-sheet base. Leverage rose and the current ratio fell over the same span; the latest liquidity measure equaled 12.1 months of reported annual operating outflow.

Financial Health Signals

Financial health score not available

Acumen Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/7

Acumen Pharmaceuticals, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Acumen Pharmaceuticals, Inc. reported a net loss of $121.3M while operations used $115.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Acumen Pharmaceuticals, Inc. reported an operating loss of $123.8M against $4.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$32.5M

YoY+22.0%

QoQ-54.0%

Acumen Pharmaceuticals, Inc.'s EBITDA was -$32.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 22.0% from the same quarter a year earlier. Against the prior quarter it is down 54.0%.

Net Income

-$32.7M

YoY+20.1%

QoQ-57.8%

Acumen Pharmaceuticals, Inc. reported -$32.7M in net income in Q2 2026. This represents an increase of 20.1% from the same quarter a year earlier. Against the prior quarter it is down 57.8%.

EPS (Diluted)

-$0.45

YoY+33.8%

QoQ-36.4%

Acumen Pharmaceuticals, Inc. earned -$0.45 per diluted share (EPS) in Q2 2026. This represents an increase of 33.8% from the same quarter a year earlier. Against the prior quarter it is down 36.4%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$18.1M

YoY+43.2%

QoQ+25.1%

Acumen Pharmaceuticals, Inc. recorded an outflow of $18.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 43.2% from the same quarter a year earlier. Against the prior quarter it is up 25.1%.

Cash & Debt

$59.4M

YoY+61.5%

QoQ+14.8%

5Y CAGR-2.9%

Acumen Pharmaceuticals, Inc. held $59.4M in cash against $11.9M in long-term debt as of Q2 2026.

Shares Outstanding

72M

YoY+19.4%

QoQ+0.1%

5Y CAGR+12.3%

Acumen Pharmaceuticals, Inc. had 72M shares outstanding in Q2 2026. This represents an increase of 19.4% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-57.1%

YoY-22.2pp

QoQ-33.4pp

Acumen Pharmaceuticals, Inc.'s ROE was -57.1% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 22.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 33.4 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$27.8M

YoY-25.1%

QoQ+68.7%

Acumen Pharmaceuticals, Inc. invested $27.8M in research and development in Q2 2026. This represents a decrease of 25.1% from the same quarter a year earlier. Against the prior quarter it is up 68.7%.

Capital Expenditures

YoY-100.0%

Acumen Pharmaceuticals, Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

ABOS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABOS quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
R&D Expenses	N/A	$104.9M+11.8%	$93.8M+121.7%	$42.3M+30.8%	$32.4M+163.0%	$12.3M+53.9%	$8.0M
SG&A Expenses	N/A	$18.9M-6.3%	$20.2M+7.4%	$18.8M+46.2%	$12.9M+76.9%	$7.3M+438.8%	$1.4M
Operating Income	N/A	-$123.8M-8.6%	-$114.0M-86.5%	-$61.1M-35.2%	-$45.2M-131.0%	-$19.6M-147.5%	-$7.9M
EBITDA	N/A	-$123.8M-8.6%	-$114.0M-86.6%	-$61.1M-35.1%	-$45.2M-130.9%	-$19.6M	N/A
Interest Expense	N/A	$4.2M+3.8%	$4.1M+600.2%	$581K	$0	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0
Net Income	N/A	-$121.3M-18.6%	-$102.3M-95.4%	-$52.4M-22.2%	-$42.9M+57.4%	-$100.6M-1273.5%	-$7.3M
EPS (Basic)	N/A	-$2.00-17.0%	-$1.71-58.3%	-$1.08-1.9%	-$1.06+78.9%	-$5.02	N/A
EPS (Diluted)	-$1.63	-$2.00-17.0%	-$1.71-58.3%	-$1.08-1.9%	-$1.06	-$5.02	N/A
Diluted Shares (Avg)	N/A	61M+0.9%	60M+23.5%	49M+19.7%	41M	20M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$27.8M-25.1%	$16.5M-34.8%	N/A	$22.0M-19.4%	$37.1M+90.1%	$25.3M+103.0%	N/A	$27.2M+143.7%
SG&A Expenses	$4.7M+2.6%	$4.7M-8.6%	N/A	$4.5M-9.4%	$4.6M-4.6%	$5.1M-4.2%	N/A	$5.0M+3.3%
Operating Income	-$32.6M+22.0%	-$21.1M+30.4%	N/A	-$26.5M+17.8%	-$41.8M-71.2%	-$30.4M-70.9%	N/A	-$32.3M-101.2%
EBITDA	-$32.5M+22.0%	-$21.1M+30.4%	N/A	-$26.5M+17.8%	-$41.7M-71.3%	-$30.4M-70.9%	N/A	-$32.2M-101.2%
Interest Expense	$1.1M+4.6%	$1.1M+4.5%	N/A	$1.1M+4.0%	$1.0M+4.2%	$1.0M+2.3%	N/A	$1.0M
Net Income	-$32.7M+20.1%	-$20.7M+28.0%	N/A	-$26.5M+11.1%	-$41.0M-99.4%	-$28.8M-93.6%	N/A	-$29.8M-129.7%
EPS (Basic)	-$0.45+33.8%	-$0.33+31.2%	-$0.41+33.9%	-$0.44+12.0%	-$0.68-100.0%	-$0.48-92.0%	-$0.62-113.8%	-$0.50-108.3%
EPS (Diluted)	-$0.45+33.8%	-$0.33+31.2%	-$0.41+33.9%	-$0.44+12.0%	-$0.68-100.0%	-$0.48-92.0%	-$0.62-113.8%	-$0.50-108.3%
Diluted Shares (Avg)	72M+19.3%	63M+4.5%	N/A	61M+0.8%	61M+0.8%	61M+1.2%	N/A	60M+10.8%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

ABOS Balance Sheet

ABOS quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$122.8M-48.6%	$239.0M-22.9%	$310.1M+57.8%	$196.6M-14.6%	$230.3M+418.4%	$44.4M
Current Assets	$122.3M-31.4%	$178.3M-27.7%	$246.6M+36.8%	$180.3M-9.2%	$198.7M+347.1%	$44.4M
Cash & Equivalents	$54.0M+51.5%	$35.6M-46.7%	$66.9M-48.6%	$130.1M+6.5%	$122.2M+179.1%	$43.8M
Short-Term Investments	$62.9M-53.7%	$135.9M-23.0%	$176.6M+271.8%	$47.5M-34.1%	$72.1M	$0
Long-Term Investments	$0-100.0%	$60.0M-4.1%	$62.6M+295.0%	$15.8M-49.9%	$31.6M	$0
Total Liabilities	$52.4M-8.3%	$57.2M+32.5%	$43.2M+452.4%	$7.8M+51.8%	$5.1M-91.8%	$63.0M
Current Liabilities	$30.0M+8.7%	$27.6M+112.8%	$13.0M+66.0%	$7.8M+51.8%	$5.1M	N/A
Non-Current Liabilities	$22.4M-24.3%	$29.6M-2.0%	$30.2M	$0	$0	N/A
Long-Term Debt	$22.4M-23.9%	$29.4M-1.6%	$29.9M	$0	N/A	N/A
Total Equity	$70.4M-61.3%	$181.8M-31.9%	$267.0M+41.4%	$188.8M-16.2%	$225.2M+1311.2%	-$18.6M
Retained Earnings	-$446.5M-37.3%	-$325.1M-45.9%	-$222.8M-30.7%	-$170.4M-33.6%	-$127.6M-373.1%	-$27.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$116.0M-32.5%	$133.6M-34.6%	$122.8M-48.6%	$142.2M-46.7%	$171.9M-40.5%	$204.5M-32.1%	$239.0M-22.9%	$267.0M-6.8%
Current Assets	$115.5M-22.2%	$133.1M-14.1%	$122.3M-31.4%	$132.2M-36.4%	$148.4M-44.4%	$154.9M-39.4%	$178.3M-27.7%	$207.6M-5.0%
Cash & Equivalents	$59.4M+61.5%	$51.8M+71.7%	$54.0M+51.5%	$46.8M+41.1%	$36.8M-45.8%	$30.2M-35.7%	$35.6M-46.7%	$33.2M-65.0%
Short-Term Investments	$50.8M-52.4%	$76.6M-35.6%	$62.9M-53.7%	$79.8M-52.3%	$106.6M-44.6%	$119.0M-42.1%	$135.9M-23.0%	$167.2M+38.7%
Long-Term Investments	$0-100.0%	$0-100.0%	$0-100.0%	$9.4M-83.9%	$22.8M+9.0%	$48.8M+10.6%	$60.0M-4.1%	$58.6M-13.0%
Total Liabilities	$58.7M+7.2%	$46.2M-5.7%	$52.4M-8.3%	$49.0M-1.5%	$54.8M+21.9%	$49.0M+25.7%	$57.2M+32.5%	$49.8M+716.2%
Current Liabilities	$46.8M+88.4%	$29.2M+51.3%	$30.0M+8.7%	$22.0M+10.3%	$24.9M+61.8%	$19.3M+128.0%	$27.6M+112.8%	$19.9M+226.6%
Non-Current Liabilities	$11.9M-60.3%	$16.9M-42.9%	$22.4M-24.3%	$27.1M-9.3%	$30.0M+1.2%	$29.6M-2.7%	$29.6M-2.0%	$29.9M
Long-Term Debt	$11.9M-60.2%	$16.9M-42.7%	$22.4M-23.9%	$27.1M-8.8%	$29.9M+1.7%	$29.5M-2.3%	$29.4M-1.6%	$29.7M
Total Equity	$57.3M-51.1%	$87.5M-43.8%	$70.4M-61.3%	$93.2M-57.1%	$117.1M-52.0%	$155.5M-40.6%	$181.8M-31.9%	$217.2M-22.5%
Retained Earnings	-$499.9M-26.6%	-$467.2M-32.0%	-$446.5M-37.3%	-$421.3M-46.3%	-$394.9M-52.9%	-$353.9M-48.9%	-$325.1M-45.9%	-$288.0M-39.6%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

ABOS Cash Flow Statement

ABOS quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$91.8M	-$115.5M-34.0%	-$86.2M-100.2%	-$43.1M-22.5%	-$35.2M-95.7%	-$18.0M-141.1%	-$7.5M
Depreciation & Amortization	N/A	$58K-7.9%	$63K+3.3%	$61K+90.6%	$32K+700.0%	$4K	N/A
Stock-Based Compensation	N/A	$9.9M+2.3%	$9.6M+56.8%	$6.1M+100.8%	$3.1M+232.0%	$922K+498.7%	$154K
Capital Expenditures	$0	$88K+450.0%	$16K-23.8%	$21K-87.0%	$161K+302.5%	$40K	N/A
Free Cash Flow	-$91.8M	-$115.6M-34.1%	-$86.2M-100.1%	-$43.1M-22.0%	-$35.3M-96.2%	-$18.0M	N/A
Investing Cash Flow	$79.0M	$133.9M+178.9%	$48.0M+128.0%	-$171.7M-538.1%	$39.2M+137.6%	-$104.1M	N/A
Financing Cash Flow	$35.5M	-$34K-100.5%	$6.9M-95.4%	$151.8M+3784.1%	$3.9M-98.1%	$200.5M+348.7%	$44.7M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$18.1M+43.2%	-$24.1M+29.3%	-$19.1M+29.8%	-$30.5M-24.0%	-$31.8M-92.4%	-$34.1M-91.1%	-$27.2M-227.3%	-$24.6M-90.6%
Depreciation & Amortization	$11K-31.3%	$12K-20.0%	$12K-14.3%	$15K-6.3%	$16K-5.9%	$15K-6.3%	$14K-26.3%	$16K+23.1%
Stock-Based Compensation	$2.5M+1.0%	$2.4M-3.2%	N/A	$2.5M+5.3%	$2.5M+1.1%	$2.5M-0.4%	N/A	$2.3M+46.1%
Capital Expenditures	$0-100.0%	$0-100.0%	$0	$0	$9K+80.0%	$79K+618.2%	$0-100.0%	$0-100.0%
Free Cash Flow	-$18.1M+43.2%	-$24.1M+29.5%	-$19.1M+29.8%	-$30.5M-24.0%	-$31.8M-92.4%	-$34.2M-91.4%	-$27.2M-226.8%	-$24.6M-90.5%
Investing Cash Flow	$26.0M-32.4%	-$13.8M-148.1%	$26.3M-11.5%	$40.5M+499.8%	$38.5M+2.1%	$28.7M+411.7%	$29.7M+160.8%	-$10.1M+89.0%
Financing Cash Flow	-$278K	$35.7M+99383.3%	$2K+122.2%	$0+100.0%	$0+100.0%	-$36K-100.5%	-$9K-100.0%	-$42K-100.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ABOS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ABOS quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Return on Equity	-172.3%-116.0pp	-56.3%-36.7pp	-19.6%+3.1pp	-22.7%+22.0pp	-44.7%	N/A
Return on Assets	-98.8%-56.0pp	-42.8%-25.9pp	-16.9%+4.9pp	-21.8%+21.9pp	-43.7%-27.2pp	-16.5%
Current Ratio	4.07-2.4x	6.46-12.6x	19.01-4.1x	23.08-15.5x	38.60	N/A
Debt-to-Equity	0.32+0.2x	0.160.0x	0.11+0.1x	0.000.0x	0.02	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-57.1%-22.2pp	-23.7%-5.2pp	N/A	-28.4%-14.7pp	-35.0%-26.6pp	-18.5%-12.8pp	N/A	-13.7%-9.1pp
Return on Assets	-28.2%-4.4pp	-15.5%-1.4pp	N/A	-18.6%-7.4pp	-23.8%-16.7pp	-14.1%-9.1pp	N/A	-11.2%-6.6pp
Current Ratio	2.47-3.5x	4.55-3.5x	4.07-2.4x	6.02-4.4x	5.97-11.4x	8.02-22.2x	6.46-12.6x	10.43-25.4x
Debt-to-Equity	0.210.0x	0.190.0x	0.32+0.2x	0.29+0.2x	0.26+0.1x	0.19+0.1x	0.160.0x	0.14+0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Acumen Pharmaceuticals, Inc. ABOS	FY2025	N/A	-$121.3M	N/A	$201.8M	—
CervoMed Inc. CRVO	FY2025	$4.0M	-$27.0M	N/A	$38.9M	44/100
Immunic, Inc. IMUX	FY2025	N/A	-$97.2M	N/A	$155.8M	—
Ovid Therapeutics Inc. OVID	FY2025	$7.3M	-$17.4M	N/A	$525.4M	65/100
XBiotech Inc XBIT	FY2025	N/A	-$45.5M	N/A	$66.8M	—
Atara Biotherapeutics, Inc ATRA	FY2025	$120.8M	$32.7M	27.1%	$94.2M	63/100

Where Acumen Pharmaceuticals, Inc. Ranks

Frequently Asked Questions

Is Acumen Pharmaceuticals, Inc. profitable?

No, Acumen Pharmaceuticals, Inc. (ABOS) reported a net income of -$121.3M in fiscal year 2025.

What is Acumen Pharmaceuticals, Inc.'s EBITDA?

Acumen Pharmaceuticals, Inc. (ABOS) had EBITDA of -$123.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Acumen Pharmaceuticals, Inc. have?

As of fiscal year 2025, Acumen Pharmaceuticals, Inc. (ABOS) had $54.0M in cash and equivalents against $22.4M in long-term debt.

What is Acumen Pharmaceuticals, Inc.'s return on equity (ROE)?

Acumen Pharmaceuticals, Inc. (ABOS) has a return on equity of -172.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Acumen Pharmaceuticals, Inc.'s free cash flow?

Acumen Pharmaceuticals, Inc. (ABOS) recorded an outflow of $115.6M in free cash flow during fiscal year 2025. This represents a -34.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Acumen Pharmaceuticals, Inc.'s operating cash flow?

Acumen Pharmaceuticals, Inc. (ABOS) recorded an outflow of $115.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Acumen Pharmaceuticals, Inc.'s total assets?

Acumen Pharmaceuticals, Inc. (ABOS) had $122.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Acumen Pharmaceuticals, Inc.'s capital expenditures?

Acumen Pharmaceuticals, Inc. (ABOS) invested $88K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Acumen Pharmaceuticals, Inc. spend on research and development?

Acumen Pharmaceuticals, Inc. (ABOS) invested $104.9M in research and development during fiscal year 2025.

How many shares does Acumen Pharmaceuticals, Inc. have outstanding?

Acumen Pharmaceuticals, Inc. (ABOS) had 72M shares outstanding as of fiscal year 2025.

What is Acumen Pharmaceuticals, Inc.'s current ratio?

Acumen Pharmaceuticals, Inc. (ABOS) had a current ratio of 4.07 as of fiscal year 2025, which is generally considered healthy.

What is Acumen Pharmaceuticals, Inc.'s debt-to-equity ratio?

Acumen Pharmaceuticals, Inc. (ABOS) had a debt-to-equity ratio of 0.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Acumen Pharmaceuticals, Inc.'s return on assets (ROA)?

Acumen Pharmaceuticals, Inc. (ABOS) had a return on assets of -98.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Acumen Pharmaceuticals, Inc.'s P/E ratio?

Acumen Pharmaceuticals, Inc. (ABOS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $201.8M as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Acumen Pharmaceuticals, Inc.'s price-to-sales ratio?

Acumen Pharmaceuticals, Inc. (ABOS) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $201.8M as of Sep 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Acumen Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Acumen Pharmaceuticals, Inc. (ABOS) held $116.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $115.5M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Acumen Pharmaceuticals, Inc.'s Piotroski F-Score?

Acumen Pharmaceuticals, Inc. (ABOS) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Acumen Pharmaceuticals, Inc.'s earnings high quality?

Acumen Pharmaceuticals, Inc. (ABOS) reported a net loss of $121.3M while operations used $115.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Acumen Pharmaceuticals, Inc. cover its interest payments?

Acumen Pharmaceuticals, Inc. (ABOS) reported an operating loss of $123.8M against $4.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.